The FDA's Final Rule Overturned: What’s Next for Labs?
The recent court ruling overturning the FDA’s final rule on laboratory-developed tests (LDTs) has reshaped the regulatory landscape—but what happens next?
Join Sarah Clancey Overton, a leading expert in regulatory affairs, as she breaks down the court’s decision, discusses potential FDA and congressional responses, and explores what this means for the future of lab innovation.
Watch Now!
Meet the team:
Sarah has over 20 years of healthcare industry experience working for multiple Fortune 500 companies including Cardinal Health and Novartis. Most recently Sarah has over 15 years in NGS, with a focus on oncology diagnostics and specializing in revenue cycle management including billing, collections, market access and reimbursement. Sarah has led multiple RCM teams at laboratories including Genoptix, Adaptive Biotechnologies, Cooper Genomics and Velsera. Currently at Velsera, Sarah is the Director of Revenue Cycle Management and addresses client reimbursement needs and concerns, leading the revenue cycle management team and overseeing Velsera’s RCM Services offering with a focus on MolDX and Technical Assessments and maximizing laboratory revenue.
Sarah Clancey Overton
Senior Director, Revenue Cycle Management
